Vaxil Bio (VXL) AI Stock Analysis

Top Page

Vaxil Bio

(TSXV:VXL)

Select Model

Rating:43Neutral

Price Target:CAD 0.10▼(-3.00% Downside)

Action:reiterated

Date:10/29/26

The score is held down primarily by weak financial performance (no revenue, ongoing operating losses, and continued cash burn with earnings-quality concerns). Technicals add further downside risk with a clear downtrend and very weak momentum indicators. Valuation is a modest offset due to the very low P/E, but it is not strongly supportive given the underlying business and cash-flow profile.

Positive Factors

Debt-free balance sheetZero debt limits interest expense and reduces refinancing pressure, giving the company greater financial flexibility than a similarly unprofitable business with leverage. This balance-sheet conservatism can help preserve strategic options while Vaxil continues developing its oncology pipeline.

Negative Factors

No reported revenueNo reported revenue shows that Vaxil has not yet demonstrated recurring commercial traction from its biotechnology activities. Without product sales or operating revenue, future progress depends on successfully advancing candidates toward commercialization or securing development-related monetization.

Vaxil Bio (VXL) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 398.40K
Dividend Yield: ―
Average Volume (3M): 4,457
Price to Earnings (P/E): 1.0
Beta (1Y): -0.82
Revenue Growth: ―
EPS Growth: ―
Country: Canada
Employees: 3
Sector: General
Sector Strength: 55
Industry: Biotechnology

Vaxil Bio Business Overview & Revenue Model

Company Description

Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infect...

How the Company Makes Money

Publicly available information sufficient to describe Vaxil Bio’s recurring, product-based revenue streams is null. As a clinical-stage/early-stage biotechnology company, its potential (and typical) monetization pathways would generally include (i) o...

Vaxil Bio Financial Statement Overview

Summary

Overall fundamentals are weak: no reported revenue, persistent negative EBIT, and ongoing negative operating cash flow/free cash flow (cash burn). The balance sheet is a partial strength with zero debt and positive equity, but positive net income in 2025/TTM alongside negative operating cash flow raises earnings-quality concerns.

Income Statement

22Negative

Balance Sheet

58Neutral

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	-2,000	-25.00K
EBITDA	-255.00K	-179.00K	-30.00K	-252.00K	-582.00K	-961.00K
Net Income	387.00K	522.00K	-178.00K	-254	-584.00K	-986.00K
Balance Sheet
Total Assets	1.22M	1.37M	733.00K	976.00K	1.54M	2.29M
Cash, Cash Equivalents and Short-Term Investments	464.00K	671.00K	714.00K	938.00K	1.51M	2.24M
Total Debt	0	0	0	0	0	0
Total Liabilities	30.00K	5,000	17.00K	85.00K	405.00K	585.00K
Stockholders Equity	1.19M	1.36M	716.00K	891.00K	1.14M	1.70M
Cash Flow
Free Cash Flow	-276.00K	-170.00K	-240.00K	-561.00K	-734.00K	-1.08M
Operating Cash Flow	-276.00K	-170.00K	-240.00K	-561.00K	-734.00K	-1.08M
Investing Cash Flow	266.00K	266.00K	-250.00K	0	0	0
Financing Cash Flow	127.00K	127.00K	0	0	0	1.81M

Vaxil Bio Technical Analysis

Technical Analysis SentimentNegative

Last Price0.10

Price Trends

50DMA0.15Negative

100DMA0.16Negative

200DMA0.17Negative

Market Momentum

MACD-0.01Positive

RSI20.92Positive

STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VXL, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.15, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 20.92 is Positive, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VXL.

Vaxil Bio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TSE:VXL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TSE:DTC	43Neutral	CAD 26.53M	-3.17	-424.91%	―	―	-54.70%
TSE:VXL	43Neutral	CAD 398.40K	1.00	34.52%	―	―	―
TSE:MDNA	40Underperform	CAD 35.32M	-2.06	-360.29%	―	―	-33.27%
TSE:BCT	39Underperform	CAD 37.55M	-0.33	-170.70%	―	―	87.90%
TSE:BIOV	29Underperform	CAD 2.04M	-0.91	69.89%	―	―	―

* General Sector Average

Performance Comparison

TSE:VXL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:VXL	Vaxil Bio	0.10	-0.07	-41.18%
TSE:MDNA	Medicenna Therapeutics	0.46	-1.04	-69.67%
TSE:BCT	BriaCell Therapeutics	4.30	-9.65	-69.18%
TSE:BIOV	Biovaxys Technology Corp	0.07	-0.19	-73.08%
TSE:DTC	Defence Therapeutics Inc	0.35	-0.45	-56.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026

Vaxil Bio AI Stock Analysis